ClinicalTrials.gg

Program

apixaban

Also written as “Apixaban”, “Apixaban 5 MG” and “Apixaban 5 mg Oral Tablet”.

Its studies are mostly in Venous Thrombosis · Atrial Fibrillation · Thrombosis · Acute Coronary Syndrome · Venous Thromboembolism, led by 7 companies.

Furthest: phase 4, since Jun 6, 201337 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb260 open or runningphase 4since Jun 6, 2013Nov 22, 2004none ahead
Pfizer60 open or runningphase 4since Feb 5, 2014Nov 5, 2008none ahead
Artivion10 open or runningphase 3since Oct 9, 2019Oct 9, 2019none ahead
Dexa Medica Group10 open or runningphase 1since Feb 5, 2025Feb 5, 2025none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Sep 4, 2023Sep 4, 2023none ahead
scotmann-pharmaceuticals10 open or runningphase 2since Oct 21, 2021Oct 21, 2021none ahead
TAHO Pharmaceuticals10 open or runningearly phase 1since Jul 24, 2023Jul 24, 2023none ahead

Also a collaborator on its studies: link-medical-research-ab, parexel and pt-equilab-international.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since Nov 22, 2004.

  1. Jan 10, 20143 phase 1 studiesBristol-Myers Squibb · NCT02034591, NCT02034578, NCT02034565
  2. Feb 5, 2014Phase 4 study in Atrial FibrillationPfizer · NCT02100228 · 1,500 enrolled · United States, Belgium, Canada and more
  3. Mar 28, 2014Phase 1 study in ThrombosisBristol-Myers Squibb · NCT02101112 · 69 enrolled
  4. Oct 9, 20142 phase 1 studies in N/A - Healthy SubjectsBristol-Myers Squibb · NCT02262533, NCT02262520
  5. Jan 21, 2015Phase 3 study in LymphomaBristol-Myers Squibb · NCT02369653 · 512 enrolled · United States, Australia, Belgium and more
  6. Apr 9, 2015Phase 4 study in Acute Coronary SyndromeBristol-Myers Squibb · NCT02415400 · 4,614 enrolled · United States, Argentina, Australia and more
  7. May 26, 2015Phase 4 study in Venous ThromboembolismBristol-Myers Squibb · NCT02464969 · 229 enrolled · United States, Australia, Austria and more
  8. Sep 19, 2016Phase 1 study in Venous ThromboembolismBristol-Myers Squibb · NCT02912234 · 20 enrolled · United States
  9. Nov 18, 2016Phase 2 study in ThrombosisBristol-Myers Squibb · NCT02981472 · 192 enrolled · United States, Argentina, Australia and more
  10. Oct 9, 2019Artivion's first study: phase 3 study in Aortic Valve DiseaseNew to ArtivionArtivion · NCT04142658 · 863 enrolled · United States
  11. Oct 21, 2021scotmann-pharmaceuticals's first study: phase 2 study in COVID-19New to scotmann-pharmaceuticalsscotmann-pharmaceuticals · NCT05088928 · 40 enrolled · Pakistan
  12. Jul 24, 2023TAHO Pharmaceuticals's first study: early phase 1 study in FastingNew to TAHO PharmaceuticalsTAHO Pharmaceuticals · NCT05995119 · 12 enrolled · United States
  13. Sep 4, 2023Humanis Saglık Anonim Sirketi's first study: phase 1 study in Antithrombic DrugNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06043297 · 30 enrolled · India
  14. Feb 5, 2025Dexa Medica Group's first study: phase 1 study in HealthNew to Dexa Medica GroupDexa Medica Group · NCT06817811 · 24 enrolled · Indonesia

TargetBeta

F10 →read by rule
“Coagulation factor X inhibitor”ChEMBL 37, by rule

Other programs on F10

ProgramCompanyFurthest phaseStudies
RivaroxabanruleBayerphase 477
emicizumabruleHoffmann-La Rochephase 413
Factor Xrulekedrion-s-p-aphase 31

Studies

All 37 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06817811Health · Indonesia1CompletedDexa Medica GroupApr 24, 202124
NCT06043297Antithrombic Drug · India1CompletedHumanis Saglık Anonim SirketiMar 6, 202330
NCT05995119Fasting · United StatesEarly 1CompletedTAHO PharmaceuticalsDec 28, 202212
NCT05088928COVID-19 · Pakistan2UNKNOWNscotmann-pharmaceuticalsMay 30, 202240
NCT04142658Aortic Valve Disease · United States3TerminatedArtivionDec 12, 2022863
NCT02981472Thrombosis · United States, Argentina, Australia and more2CompletedBristol-Myers SquibbOct 18, 2021192
NCT02912234Venous Thromboembolism · United States1CompletedBristol-Myers SquibbOct 201620
NCT02464969Venous Thromboembolism · United States, Australia, Austria and more4CompletedBristol-Myers SquibbApr 30, 2024229
NCT02415400Acute Coronary Syndrome · United States, Argentina, Australia and more4CompletedBristol-Myers SquibbNov 10, 20184,614
NCT02369653Lymphoma · United States, Australia, Belgium and more3CompletedBristol-Myers SquibbJul 7, 2021512
NCT02262533N/A - Healthy Subjects · United States1CompletedBristol-Myers SquibbJun 200715
NCT02262520N/A - Healthy Subjects1CompletedBristol-Myers SquibbMar 200624
NCT02101112Thrombosis1CompletedBristol-Myers SquibbMay 201469
NCT02100228Atrial Fibrillation · United States, Belgium, Canada and more4CompletedPfizerFeb 8, 20171,500
NCT02034591Healthy Subjects · United States1CompletedBristol-Myers SquibbNov 201137
NCT02034578Healthy Volunteers · United States1CompletedBristol-Myers SquibbAug 201175
NCT02034565Healthy Volunteers · United States1CompletedBristol-Myers SquibbMar 201048
NCT01884350Non-valvular Atrial Fibrillation · Belgium, France, Germany and more4CompletedBristol-Myers SquibbJan 20, 20161,217
NCT01884337Anticoagulation · India4CompletedBristol-Myers SquibbJun 4, 2018557
NCT01780987Venous Thrombosis · Japan3CompletedPfizerSep 201480
NCT01707394Thromboembolism · United States, Australia, Canada and more1CompletedBristol-Myers SquibbJun 30, 202049
NCT01437839Healthy · Singapore1CompletedPfizerOct 201122
NCT01340586Kidney Failure, Chronic · United States1CompletedBristol-Myers SquibbSep 201118
NCT01195727Venous Thromboembolism · United States, Belgium, Canada and more1TerminatedBristol-Myers SquibbJun 14, 201213
NCT00914641Thrombosis · United States1CompletedPfizerAug 200916
NCT00852397Acute Coronary Syndrome · Japan2TerminatedPfizerDec 2010151
NCT00831441Acute Coronary Syndrome · United States, Argentina, Australia and more3TerminatedBristol-Myers SquibbMar 20117,484
NCT00787150Atrial Fibrillation · Japan2CompletedPfizerSep 2009222
NCT00643201Venous Thrombosis · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbMar 20135,614
NCT00633893Venous Thrombosis · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbAug 20122,711
NCT00496769Atrial Fibrillation · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbNov 30, 20106,421
NCT00457002Venous Thrombosis · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbMay 20116,758
NCT00452530Venous Thrombosis · Austria, Belgium, Brazil and more3CompletedBristol-Myers SquibbJan 20093,221
NCT00412984Atrial Fibrillation · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbMay 25, 201120,976
NCT00313300Acute Coronary Syndrome · United States, Austria, Belgium and more2CompletedBristol-Myers SquibbMay 20081,741
NCT00252005Venous Thrombosis · United States, Australia, Austria and more2CompletedBristol-Myers SquibbFeb 2007520
NCT00097357Venous Thrombosis · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbDec 20051,238

How it is read

Names in the registry

  • “Apixaban”, 38 entries
  • “Apixaban 5 MG”, 2 entries
  • “apixaban”, 2 entries
  • “Apixaban 5 mg Oral Tablet”, 1 entry
  • “Apixaban 5MG”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.